Transmission congénitale de la brucellose bovine d’une génération à l’autre

Plommet M., Renoux G., Philippon Alain, Gestin J., Fenster-Bank R. Transmission congénitale de la brucellose bovine d’une génération à l’autre. In: Bulletin de l'Académie Vétérinaire de France tome 124 n°1, 1971. pp. 53-59

Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study

<p>Abstract</p> <p>Background</p> <p>The anti-VEGF antibody bevacizumab associated with an irinotecan or oxaliplatin-based chemotherapy was proved to be superior to the chemotherapy alone in first or second line treatment of metastatic colorectal cancer (mCRC). However, it was reported to have no efficacy in 3^rdor later-line, alone or with 5FU. The aim of this study was to evaluate the activity of bevacizumab combined with FOLFIRI or FOLFOX in mCRC who have failed prior chemotherapy with fluoropyrimidine plus irinotecan and/or oxaliplatin.</p> <p>Methods</p> <p>Thirty one consecutive patients treated between May 2005 and October 2006 were included in this retrospective study. All of them have progressed under a chemotherapy with fluoropyrimidine plus irinotecan and/or oxaliplatin and received bevacizumab (5 mg/kg) in combination with FOLFIRI or simplified FOLFOX4 every 14 days.</p> <p>Results</p> <p>Ten patients (32.2%) had an objective response (1 CR, 9 PR) and 12 (38.8%) were stabilized. The response and disease control rates were 45.4% and 100% when bevacizumab was administered in 2^ndor 3^rdline and 25% and 55% in 4^thor later line respectively (p = 0.024 and p = 0.008). Among the patients who had previously received the same chemotherapy than that associated with bevacizumab (n = 28) the overall response rate was 35.7% and 39.3% were stabilized. Median progression free survival (PFS) and overall survival (OS) were of 9.7 and 18.4 months respectively. Except a patient who presented a hypertension associated reversible posterior leukoencephalopathy syndrome, tolerance of bevacizumab was acceptable. A rectal bleeding occurred in one patient, an epistaxis in five. Grade 1/2 hypertension occurred in five patients.</p> <p>Conclusion</p> <p>This study suggests that bevacizumab combined with FOLFOX or FOLFIRI may have the possibility to be active in chemorefractory and selected mCRC patients who did not receive it previously.</p

Traitement préventif de l’avortement brucellique de la vache par le chlorhydrate d’oxytétracycline

Quarante-cinq génisses réparties en 3 lots (A, B, C) de 15 ont été inoculées par voie conjonctivale par la souche Brucella abortus 544, respectivement aux 2e, 4e et 6e mois de la gestation. Dans chaque lot, un groupe 1 (5 génisses) n’a reçu aucun traitement ; un groupe 2 (5 génisses) a reçu une injection intrapéritonéale de 10 g d’oxyté- tracycline en solution aqueuse un mois après l’inoculation ; un groupe 3 a reçu 3 injections aux 3e, 5e et 7e mois de gestation. Alors qu’une seule vache du groupe témoin 1 a donné un veau normal à terme, il y en a eu 3 dans le groupe 2 dont 2 dans le lot A et 6 dans le groupe 3, dont 4 dans le lot A. Les vaches ont été abattues six semaines après leur vêlage, et le degré d’infection des carcasses établi par numération des Brucella dans les organes et ganglions. Les vaches des groupes 1 et 2 sont en moyenne infectées au même degré ; par contre, celles du groupe 3 sont très peu infectées. Cinq vaches sont indemnes de brucellose à l’abattage (4 dans les groupes traités 3 fois, 1 dans un groupe traité une fois). Ces résultats, ajoutés à ceux obtenus dans un travail antérieur, permettent de proposer deux schémas de traitement préventif des avortements brucelliques dans la nature, selon que dans le troupeau la maladie est d’apparition récente ou ancienne. Dans le 1er cas, traitement simultané de tous les animaux par une injection intrapéri¬ tonéale de 10 g d’oxytétracycline ; dans le second, 2 ou 3 injections de 10 g au début de la gestation (2-3e mois) espacées de 1 mois-lmois et demi.Plommet M., Fenster-Bank R., Gestin J., Lagneau Fernand. Traitement préventif de l’avortement brucellique de la vache par le chlorhydrate d’oxytétracycline. In: Bulletin de l'Académie Vétérinaire de France tome 124 n°10, 1971. pp. 495-503

Synthesis of new semi-rigid chelating agents for samarium-153

This study describes a simple, efficient synthesis pathway from trans-1,2-diaminocyclohexane that provides access to a new class of semi-rigid polyamine, polycarboxylic, and polyphosphonic ligands. The key steps in synthesis were the functionalisation (with an appropriate branching group) of a bisphosphonate diaminocyclohexane derivative and the introduction of methanephosphonic functions by a rarely used method

Synthesis of New Semi-Rigid Chelating Agents for Samarium-153.

Abstract not availableJRC.E-Institute for Transuranium Elements (Karlsruhe

Influence of trans-1,2-diaminocyclohexane structure and mixed carboxylic/phosphonic group combinations on samarium-153 chelation capacity and stability

A simple procedure was developed to compare chelating agents for 153Sm complexes as a preliminary step to synthesise bifunctional analogues. Several variables affecting the efficiency of complex stability were investigated, such as the pre-organisation concept, cavity size, and the nature of coordination sites. Four semi-rigid agents incorporating carboxylic and/or phosphonic groupings fixed at trans-1,2-diaminocyclohexane were evaluated for their 153Sm chelation properties, and competition studies were performed. Data on the stability of the best chelating agent compound 3: trans-cyclohexane-1,2-bis(aminomethylphosphonic)-N,N′-bis(ethyl-2- iminodiacetic acid) in human serum are presented

Bovine pancreatic preproelastases I and II: comparison of nucleotide and amino acid sequences and tissue specific expression.

International audienceClones encoding bovine preproelastases I and II were isolated from a pancreatic cDNA library and were sequenced in order to define the structural characteristics of these enzymes. The bovine 947- and 884-nucleotide preproelastase I and II cDNAs encode proteins containing a signal peptide of the same length (16 amino acids), but with a slightly different number of amino acids for the activation peptide (10 and 12, respectively) and the mature enzyme (240 and 241, respectively). Considering amino acid sequences, each enzyme shares a high degree of identity (76-86%) within species. In contrast, only 55.3% identity is found between bovine elastases I and II. This difference could explain partly their own specificity. Analysis of the expression of the elastases in various bovine tissues demonstrated that they are specifically expressed in high levels in the pancreatic gland. These two approaches (structure and expression) allowed us to characterize the bovine pancreatic elastases I and II